MacroChem Appoints Bernard R. Patriacca Vice President & CFO

Former VP/controller of Summit Autonomous brings broad industry, public

offering, M&A experience, record of team motivation in operations and general

management



Apr 26, 2001, 01:00 ET from MacroChem Corporation

    LEXINGTON, Mass., April 26 /PRNewswire/ --MacroChem Corporation
 (Nasdaq:   MCHM) announced today that it has appointed Bernard R. Patriacca as
 vice president and chief financial officer, effective immediately.
     MacroChem Corporation is a pharmaceutical company developing innovative
 through-the-skin prescription products for a wide range of clinically
 important and commercially significant human and veterinary health conditions.
 It is currently completing a Phase 3 trial for Topiglan(R), a novel topical
 agent for erectile dysfunction, which affects more than 76 million men in the
 industrialized world.
     Mr. Patriacca was formerly vice president and controller of Summit
 Autonomous, a leader in laser vision-correction instruments acquired by Alcon
 Laboratories last year. He brings to MacroChem a strong record at Summit of
 raising $70 million in a public offering, the acquisition of a $220 million
 competing company, and support for the 2000 sale of Summit to Alcon for almost
 $1 billion. Prior to Summit, Mr. Patriacca operated a financial and operations
 consultancy serving four large private and public corporations. His career
 began in 1968 at Price Waterhouse, and was followed by 18 years building
 Dunkin' Donuts Corporation from a small local franchiser into a $1 billion
 multinational food service company, where he rose to senior vice president and
 chief financial officer.
     "I am pleased that Mr. Patriacca shares my vision of the opportunity to
 capitalize on and build upon MacroChem's strong fundamentals," said MacroChem
 president and CEO Robert Palmisano, former president and CEO of Summit
 Autonomous, who was appointed to his current position by the MacroChem board
 of directors earlier this month.
     "Both Mr. Patriacca and I are most appreciative of the strong support
 provided by MacroChem's former CFO Kenneth L. Rice Jr., who resigned earlier
 this month to accept a business development opportunity in a privately held
 company," Mr. Palmisano said. "We believe shareholders and the investment
 community will be impressed by the smooth transition these two executives have
 assured."
     Mr. Patriacca is a Certified Public Accountant. He holds bachelors of arts
 and sciences degrees, and a masters in business administration, from
 Northeastern University. He is also a graduate of the Harvard Business School
 Program for Financial Executives.
 
     To the extent that this press release discusses matters relating to the
 development of future products, these are forward-looking statements and are
 subject to various risk factors that could cause actual results to differ
 materially from those expressed in the forward-looking statements. The
 relevant risk factors are set forth in MacroChem's annual report on Form 10-K
 as filed with the SEC and include, without limitation, risks regarding product
 development, clinical trials, dependence on third parties for development and
 licensing arrangements, and risks involving regulatory approval of products,
 and patents and licenses.
     Visit our web site at: http://www.macrochem.com or http://www.mchm.com
 
                     MAKE YOUR OPINION COUNT -  Click Here
                http://tbutton.prnewswire.com/prn/11690X87618883
 
 

SOURCE MacroChem Corporation
    LEXINGTON, Mass., April 26 /PRNewswire/ --MacroChem Corporation
 (Nasdaq:   MCHM) announced today that it has appointed Bernard R. Patriacca as
 vice president and chief financial officer, effective immediately.
     MacroChem Corporation is a pharmaceutical company developing innovative
 through-the-skin prescription products for a wide range of clinically
 important and commercially significant human and veterinary health conditions.
 It is currently completing a Phase 3 trial for Topiglan(R), a novel topical
 agent for erectile dysfunction, which affects more than 76 million men in the
 industrialized world.
     Mr. Patriacca was formerly vice president and controller of Summit
 Autonomous, a leader in laser vision-correction instruments acquired by Alcon
 Laboratories last year. He brings to MacroChem a strong record at Summit of
 raising $70 million in a public offering, the acquisition of a $220 million
 competing company, and support for the 2000 sale of Summit to Alcon for almost
 $1 billion. Prior to Summit, Mr. Patriacca operated a financial and operations
 consultancy serving four large private and public corporations. His career
 began in 1968 at Price Waterhouse, and was followed by 18 years building
 Dunkin' Donuts Corporation from a small local franchiser into a $1 billion
 multinational food service company, where he rose to senior vice president and
 chief financial officer.
     "I am pleased that Mr. Patriacca shares my vision of the opportunity to
 capitalize on and build upon MacroChem's strong fundamentals," said MacroChem
 president and CEO Robert Palmisano, former president and CEO of Summit
 Autonomous, who was appointed to his current position by the MacroChem board
 of directors earlier this month.
     "Both Mr. Patriacca and I are most appreciative of the strong support
 provided by MacroChem's former CFO Kenneth L. Rice Jr., who resigned earlier
 this month to accept a business development opportunity in a privately held
 company," Mr. Palmisano said. "We believe shareholders and the investment
 community will be impressed by the smooth transition these two executives have
 assured."
     Mr. Patriacca is a Certified Public Accountant. He holds bachelors of arts
 and sciences degrees, and a masters in business administration, from
 Northeastern University. He is also a graduate of the Harvard Business School
 Program for Financial Executives.
 
     To the extent that this press release discusses matters relating to the
 development of future products, these are forward-looking statements and are
 subject to various risk factors that could cause actual results to differ
 materially from those expressed in the forward-looking statements. The
 relevant risk factors are set forth in MacroChem's annual report on Form 10-K
 as filed with the SEC and include, without limitation, risks regarding product
 development, clinical trials, dependence on third parties for development and
 licensing arrangements, and risks involving regulatory approval of products,
 and patents and licenses.
     Visit our web site at: http://www.macrochem.com or http://www.mchm.com
 
                     MAKE YOUR OPINION COUNT -  Click Here
                http://tbutton.prnewswire.com/prn/11690X87618883
 
 SOURCE  MacroChem Corporation